141 related articles for article (PubMed ID: 38331087)
1. EZH2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract][Full Text] [Related]
2. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
Chen XJ; An N
J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
[TBL] [Abstract][Full Text] [Related]
4. Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer.
Lawrence CL; Baldwin AS
PLoS One; 2016; 11(10):e0165005. PubMed ID: 27764181
[TBL] [Abstract][Full Text] [Related]
5. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
7. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
[TBL] [Abstract][Full Text] [Related]
8. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
9. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
10. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
12. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
[TBL] [Abstract][Full Text] [Related]
13. The lysine methyltransferases SET and MYND domain containing 2 (Smyd2) and Enhancer of Zeste 2 (Ezh2) co-regulate osteoblast proliferation and mineralization.
Dashti P; van de Peppel J; Thaler R; Paradise CR; Stein GS; Montecino MA; van Leeuwen JPTM; van der Eerden BJ; Dudakovic A; van Wijnen AJ
Gene; 2023 Jan; 851():146928. PubMed ID: 36191822
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
Yang X; Xu L; Yang L
Eur J Med Chem; 2023 Aug; 256():115461. PubMed ID: 37156182
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
[TBL] [Abstract][Full Text] [Related]
17. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
18. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
20. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
